查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
CAR-T 融资：创投、IPO、授权协议、业务联盟、併购交易（2024 年）
市场调查报告书
商品编码
1443436

CAR-T 融资：创投、IPO、授权协议、业务联盟、併购交易（2024 年）

CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024
出版日期: | 出版商: BioInformant | 英文 207 Pages | 订单完成后即时交付

价格
简介目录

执行摘要

CAR-T 产业的资金正在飙升，而不是增加。 最初，这种趋势很微妙，但随着 Kymriah、Yescarta、Tecartus、Breyanzi、Abecma 和 Carvykti 等 CAR-T 疗法进入市场并引发融资热潮，这种趋势正在增强。 近年来，CAR-T 新创公司从渴望利用这一再生医学趋势的投资者那里获得了充足的资金。

全球有超过 170 家公司参与 CAR-T 产品和治疗的开发。 这些 CAR-T 疗法公司正在开发近 970 种早期和晚期疗法。 这些公司还拥有令人印象深刻的 98 份业务合作协议，以推进各种 CAR-T 产品候选者的开发。 其中，33个商业合作项目已揭露财务条款，交易总额达217亿美元。 如果算上未揭露条款的商业合作项目，这98个商业合作项目的总价值高达630亿美元。

在过去十年中，CAR-T 公司已获得 67 亿美元的风险投资，使他们能够投资于基础设施和产品管道。 同期，CAR-T 公司透过 IPO 融资筹集了 58 亿美元，用于加强其技术基础、临床试验项目和企业努力。

在这个拥有超过417,801 项专利记录和4,024 项授权专利的新兴行业中，大型製药公司正在寻求透过现有专利持有者的许可权进入CAR-T 领域。该行业正在变得越来越强大。 因此，过去十年CAR-T授权交易的总价值为39亿美元，预计未来十年这一总额将大幅成长。

在本报告分析的各种类型的融资中（包括 CAR-T 行业的 IPO 和许可协议、业务联盟、战略合作伙伴关係、联合开发协议和併购交易），併购交易是最大的财务交易过去10 年价值高达959 亿美元。

对于年轻的 CAR-T 产业来说，透过这些具有报告财务条款的各种交易筹集了超过 1,282.5 亿美元的资金，这是一项了不起的成就。 此外，84项CAR-T许可协议中的59项、98项业务合作协议中的65项以及27项併购交易中的11项均未揭露交易金额。 因此，如果粗略计算所有未公开金额的交易，总金额将高达2400亿美元。

目前美国 FDA 核准了六种 CAR-T 疗法：

  • Tisagenlecleucel-T (Kymriah)
  • Axicabtagene ciloleucel (Yescarta)
  • Brexcabutagene autoleucel（Tecartus）
  • Rhizocabutadiene Malaleucel (Breyanzi)
  • Idecabtagene viclucel (Abecma)
  • Tirtacabutagene autoleucel（Carvykte）

上述许多 CAR-T 疗法已获得其他监管机构（如欧洲、中国、印度）的批准。 由于 CAR-T 审批在全球范围内正在加速，因此该清单并不详尽。 根据 ClinicalTrials.gov 统计，目前有 706 个 CAR-T 计画处于临床开发阶段。

本报告分析了全球 CAR-T 细胞治疗领域的融资趋势，包括交易总数和交易金额的趋势，以及各种类型（融资轮次、IPO、併购交易、我们的交易）的趋势。调查联合开发协议、策略合作伙伴关係等详细趋势、78家主要公司的交易趋势以及整个产业的主要驱动因素。

目录

第 1 章执行摘要

第二章 CAR-T细胞疗法在全球的商业化

  • 接受 CAR-T 细胞疗法治疗的患者总数：依年份（2017-2023 年）
  • FDA 核准的 CAR-T 疗法产生的总收入（2017-2023 年）
  • FDA 核准的 CAR-T 疗法的标价

第三章 CAR-T 产业融资活动

  • CAR-T产业创投盛会
    • CAR-T公司所募集的创投总额（2014-2023年）
    • CAR-T公司所募集的创投资金：与前一年比较
    • CAR-T 公司所募集的创投（共 78 笔融资）：交易条款与金额

第四章 CAR-T细胞治疗公司IPO募集资金

  • CAR-T公司募集的IPO资金：交易条件与金额
    • Juno Therapeutics
    • Cellular Biomedicine Group
    • Xenetic Biosciences
    • Cellular Biomedicine Group
    • Autolus Therapeutics
    • Allogene Therapeutics
    • Precision BioSciences
    • Atara Biotherapeutics
    • Xenetic Biosciences
    • Cabaletta Bio
    • Atara Biotherapeutics
    • Legend Biotech
    • Mustang Bio
    • JW Therapeutics
    • Atara Biotherapeutics
    • Gracell Biotechnologies
    • Vor Biopharma
    • Adicet Bio
    • CARsgen Therapeutics
    • Xenetic Biosciences
    • Caribou Biosciences
    • Celyad Oncology
    • Adicet Bio
    • Legend Biotech
    • Kyverna Therapeutics
    • Arcellx
    • TC Biopharm
    • Celularity
    • TC BioPharm
    • Precision Biosciences
    • Legend Biotech
    • TC Biopharm
    • Vor Biopharma
    • Precigen
    • TC Biopharm
    • Celularity
    • Legend Biotech
    • Coeptis Therapeutics
    • Caribou Biosciences

第五章世界各国CAR-T许可协议实施

  • 全球 CAR-T 许可协议总数
    • CAR-T 授权协议概述：交易条款和金额

第六章 CAR-T业务合作交易

  • CAR-T 相关业务合作（协作）交易（2013-2023 年）
    • 2013年至2023年签订的CAR-T业务合作协议概览

第七章 CAR-T产业併购交易

  • 全球 CAR-T 细胞治疗领域执行的併购交易：交易条款与金额
    • Cellular Biomedicine 和 Chinese PLA General Hospital
    • Gilead Sciences 和 Kite Pharma
    • Gilead Sciences 和 Cell Design Labs
    • Novartis 和 Endocyte
    • Bristol Myers Squibb 和 Celgene
    • Xenetic Biosciences 和 Scripps Research Institute
    • Astellas Pharma 和 Xyphos Biosciences
    • BioNTech 和 Neon Therapeutics
    • resTORbio 和 Adicet Bio
    • Century Therapeutics 和 Empirica Therapeutics
    • Celularity 和 GX Acquisition
    • Cellular Biomedicine 和 CBMG Merger Sub
    • Amgen 和 Five Prime Therapeutics
    • BioNTech 和 Kite
    • ImmPACT Bio 和 Kalthera
    • Kiromic Biopharma 和 InSilico Solutions
    • Allogene Therapeutics 和 Antion Biosciences
    • FUJIFILM Corporation 和 Atara Biotherapeutics
    • FUJIFILM Corporation 和 Atara Biotherapeutics
    • Galapagos 和 CellPoint/AboundBio
    • Atossa Therapeutics 和 Dynamic Cell Therapies
    • Kite 和 Tmunity Therapeutics
    • Janssen 和 Cellular Biomedicine
    • Mustang Bio 和 uBriGene Biosciences
    • Precision Biosciences 和 Imugene
    • Oxford Biomedica 和 Institut Merieux
    • Clade Therapeutics 和 Gadeta
    • Kyowa Kirin 和 Orchard Therapeutics

第八章参与募款活动的CAR-T公司概况

  • AdAlta Ltd.
  • Adicet Bio
    • γδT 细胞
  • AffyImmune Therapeutics, Inc.
    • 亲和力调整CAR
    • 即时 CAR-T 细胞监测
  • 同种异体疗法
    • AlloCAR-T
  • Alpha Biopharma
  • Antion Biosciences
    • miCAR-T技术
  • Arcellx, Inc.
    • D域技术
    • ddCAR
    • ARC-SparX
  • Arsenal Biosciences, Inc.
  • Astellas Pharma, Inc.
    • 合作伙伴关係
  • Atara Biotherapeutics
  • Autolus Therapeutics PLC
  • AvenCell Therapeutics, Inc.
    • 可自由切换的CAR平台
  • Beam Therapeutics
  • Bellicum Pharmaceuticals, Inc.
    • GoCAR技术
    • CaspaCIDe技术
  • Biosceptre
    • 独特目标：nfP2X7
  • BioNTech SE
    • 基于新抗原的 T 细胞治疗平台
  • bluebird bio
  • Cargo Therapeutics
  • Caribou Biosciences, Inc.
    • 下一代 CRISR 技术
    • CAR-T治疗平台
  • Carina Biotech
    • LGR5 CAR-T计划
  • CARsgen Therapeutics Holdings Limited
    • CycloCAR
    • THANK-uCAR
  • Cartherics Pty Ltd
    • Cartherics CAR-T 细胞
  • Cellares
    • Cell Shuttle
  • Cellectis
  • Cellular Biomedicine Group
  • Celularity, Inc.
    • 胎盘的力量
    • NK细胞平台
    • T细胞平台
    • 外泌体平台
  • Celyad 肿瘤学
    • shRNA平台
    • shARC平台
  • Chengdu Usano Biotechnology Co., ltd. (Ucello)
  • Chimeric Therapeutics, Ltd.
    • CLTX CAR-T
    • CDH17 CAR-T
  • Clade Therapeutics
    • 平台技术
  • Coeptis Therapeutics, Inc.
    • SNAP-CAR
  • CRISPR Therapeutics
  • Currus Biologics
    • BEAT 技术
  • CytoMed Therapeutics Ltd.
    • CAR-y delta-T 细胞
  • Dynamic Cell Therapies, Inc.
    • 平台技术
  • Elicera Therapeutics
  • Galapagos NV
  • Gracell Biotechnologies
    • FasTCAR
    • TruUCAR
    • SMART CART
  • EXUMA Biotech Corp.
    • TMR CAR-T技术
  • IASO Biotherapeutics
    • 技术平台
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmPACT Bio
    • CD19/20 双特异性 CAR
    • TGF-B
  • Inceptor Bio
    • CAR-M疗法
  • Interius BioTherapeutics
  • Invectys, Inc.
    • IVS-3001：抗HLA-G CAR-T细胞
  • Juventas Cell Therapy, Ltd.
  • JW Therapeutics
    • Carteyva（勒马塞尔）
  • 加拉巴哥群岛
    • 平台技术
  • Kite Pharma (Gilead)
  • Kyverna Therapeutics
    • "更聪明" 的 CAR-T 细胞
  • Legend Biotech
    • Carvykti
  • Leucid Bio, Ltd
    • 横向CAR平台
  • Luminary Therapeutics
    • Gamma 2.0+ 平台
  • Lupagen, Inc.
    • 侧面 CAR-T 输送系统
  • MaxCyte, Inc.
  • Minerva Biotechnologies
  • Mustang Bio, Inc.
  • Noile-Immune Biotech
    • PRIME Technology
  • Novartis AG
    • Kymriah 的批准
  • OneChain Immunotherapeutics
  • Oncternal Therapeutics, Inc
  • ROR1　
  • OriCell Therapeutics
    • OriCAR
  • Oxford Biomedica PLC
    • 慢载体平台
    • 腺相关病毒平台
  • Pepromene Bio, Inc.
    • BAFFR CAR-T 细胞
  • PersonGen Bio Therapeutics (Suzhou) Co., Ltd
  • Poseida Therapeutics, Inc.
    • PiggyBac 平台
    • CasCLOVER平台
  • Precigen, Inc.
    • UltraCAR-T 平台
  • 精准生物科学
    • ARCUS基因编辑平台
  • 先见之明疗法
    • OmniCAR
    • CellPryme-M
    • CellPryme-A
  • Simnova Biotherapeutics
    • BiTE CAR-T平台
  • SOTIO Biotech B.V.
  • TC BioPharm
    • γδT 细胞
    • T细胞库
    • Co-Stim CAR-T
  • Umoja 生物製药
    • VivoVec 体内基因传递
    • RACR诱导的细胞毒性淋巴球（iCIL）
    • RACR/CAR体内细胞编程
    • 肿瘤标籤
  • Verismo Therapeutics, Inc.
    • KIR-CAR平台
  • Vor Biopharma
  • Wugen, Inc.
  • Xenetic Biosciences, Inc.
    • XBIO-020：DNase I 装甲 CAR-T
  • Xyphos Biosciences, Inc.
    • covertibleCAR 技术

图表列表

表格列表

简介目录

EXECUTIVE SUMMARY:

CAR-T industry funding isn't gaining traction, it is surging. At first, the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti have reached the marketplace and created a funding boom. In recent years, CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.

Worldwide, more than 170 companies are engaged in developing CAR-T products and therapies. These CAR-T therapy companies have developed nearly 970 early and late-stage therapies. These companies have also signed an incredible 98 collaboration deals to progress the development of various CAR-T product candidates. Of these, 33 collaboration deals have disclosed their financial terms, which account for a total of $21.7 billion in transactions. If an estimate is made for the collaboration deals that have not disclosed their terms, the total value of these 98 collaboration deals would be in the range of an astonishing $63 billion.

Over the past decade, CAR-T companies have also attracted venture capital investments worth an incredible $6.7 billion, enabling these CAR-T companies to invest in their infrastructure and product pipelines. During the same period, CAR-T companies raised an impressive $5.8 billion through IPO funding to strengthen their technology platforms, clinical trial programs, and corporate efforts.

Within this nascent industry, with over 417,801 patent records and 4,024 granted patents, large pharma has increasingly been seeking to enter the CAR-T field by licensing rights from existing patent owners. Thus, the total value of CAR-T licensing deals over the past decade accounts for another $3.9 billion in transactions and this total is expected to expand substantially in the coming decade.

Among the various financing types analyzed in this report-which include CAR-T industry IPOs, licensing deals, collaborations, strategic partnerships, co-development agreements, and M&A deals-M&A deals constitute the largest financial percentage, accounting for an astounding $95.9 billion over the past decade.

For the nascent CAR-T industry, it is a phenomenal achievement to raise more than $128.25 billion through these various deals that have reported their financial terms. Additionally, 59 of 84 CAR-T licensing deals, 65 of the 98 CAR-T collaboration deals, and 11 of the 27 CAR-T industry M&A deals did not disclose the value of their transactions. Thus, if an approximate estimate is calculated for all deals of undisclosed values, the total value would be a staggering $240 billion.

At present, six CAR-T therapies have been approved by U.S. FDA, including:

  • Tisagenlecleucel-T (Kymriah)
  • Axicabtagene ciloleucel (Yescarta)
  • Brexucabtagene autoleucel (Tecartus)
  • Lisocabtagene maraleucel (Breyanzi)
  • Idecabtagene vicleucel (Abecma)
  • Ciltacabtagene autoleucel (Carvykte)

Many of the CAR-T therapies above have been approved by other regulatory agencies, most commonly for use within the EU. Numerous CAR-T therapies have reached commercialization in other regions as well, such as Relma-cel's (Relmacabtagene) and Yikaida's (Axicabtagene ciloleucel) approval from the NMPA in China, Ebvallo's (tabelecleucel) approval from the European Commission, Actaly-cel's (Actalycabtagene autoleucel) in India, and Fucaso's (Equecabtagene autoleucel) approval in China, for example. This list is not exhaustive because CAR-T approvals are accelerating on a global scale. According to ClinicalTrials.gov, there are also an incredible 706 CAR-T programs that are in clinical phases of development.

This CAR-T market funding report summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events. Of course, it aggregates these numbers so you can understand the global impact of these funding events and how they are propelling rapid growth of the CAR-T sector at large.

It features the following information for the CAR-T cell therapy industry:

  • Financing Rounds
  • IPOs
  • Asset Agreements
  • Strategic Partnerships
  • Co-Development Agreements
  • M&A Transactions
  • Companies Profiles for CAR-T Market Competitors

You can use it to:

  • 1. Quantify CAR-T industry investments
  • 2. Identify well-capitalized companies
  • 3. Scout potential partnerships and alliances
  • 4. Understand partnerships and co-development programs for CAR-T technologies
  • 5. Identify M&A activity within the CAR-T industry

In summary, there have been hundreds of billions of dollars in financial transactions completed by CAR-T companies in recent years. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. GLOBAL COMMERCIALIZATION OF CAR-T CELL THERAPIES

  • 2.1. Total Number of Patients Treated with CAR-T Cell Therapies by Year, 2017-2023
  • 2.2. Total Sales Revenues Generated by FDA-Approved CAR-T Therapies, 2017-2023
  • 2.3. List Prices of FDA-Approved CAR-T Therapies

3. CAR-T INDUSTRY FUNDING EVENTS

  • 3.1. CAR-T Industry Venture Capital Financing Events
    • 3.1.1. Total Venture Capital Raised by CAR-T Companies, 2014 - 2023
    • 3.1.2. Year-Over-Year Comparison of Venture Capital Funding Raised by CAR-T Companies
    • 3.1.3. Venture Capital Raised by CAR-T Companies (78 Capital Raises) - Deal Terms & Values
      • 3.1.3.1. Bellicum Pharmaceuticals
      • 3.1.3.2. CRISPR Therapeutics
      • 3.1.3.3. Autolus
      • 3.1.3.4. Cellular Biomedicine Group
      • 3.1.3.5. Adicet Bio
      • 3.1.3.6. Autolus Limited
      • 3.1.3.7. Cellular Biomedicine Group
      • 3.1.3.8. JW Therapeutics
      • 3.1.3.9. Carina Biotech
      • 3.1.3.10. PeproMene Bio
      • 3.1.3.11. Precision BioSciences
      • 3.1.3.12. Cabaletta Bio
      • 3.1.3.13. Vor Biopharma
      • 3.1.3.14. Gracel Biotechnologies
      • 3.1.3.15. Mustang Bio
      • 3.1.3.16. Poseida Therapeutics
      • 3.1.3.17. BioNTech
      • 3.1.3.18. Adicet Bio
      • 3.1.3.19. Kyverna Therapeutics
      • 3.1.3.20. EXUMA Biotech
      • 3.1.3.21. IASO Biotherapeutics
      • 3.1.3.22. Legend Biotech
      • 3.1.3.23. JW Therapeutics
      • 3.1.3.24. Vor Pharma
      • 3.1.3.25. ImmPACT Bio
      • 3.1.3.26. Synthekine
      • 3.1.3.27. Gracell Biotechnologies
      • 3.1.3.28. CARsgen Therapeutics
      • 3.1.3.29. Umoja Biopharema
      • 3.1.3.30. Juventas Cell Therapy
      • 3.1.3.31. Celyad Oncology
      • 3.1.3.32. Artiva Biotherapeutics
      • 3.1.3.33. Caribou Biosciences
      • 3.1.3.34. Biosceptre
      • 3.1.3.35. Noile-Immune Biotech
      • 3.1.3.36. Arcellx
      • 3.1.3.37. Cellares Corporation
      • 3.1.3.38. Interius BioTherapeutics
      • 3.1.3.39. Synthekine
      • 3.1.3.40. Umoja Biopharma
      • 3.1.3.41. Wugen
      • 3.1.3.42. Mnemo Therapeutics
      • 3.1.3.43. AvenCell
      • 3.1.3.44. Currus Biologics
      • 3.1.3.45. Juventas Cell Therapy
      • 3.1.3.46. Carina Biotech
      • 3.1.3.47. IASO Biotherapeutics
      • 3.1.3.48. Cellular Biomedicines
      • 3.1.3.49. AffyImmune Therapeutics
      • 3.1.3.50. Leucid Bio
      • 3.1.3.51. Clade Therapeutics
      • 3.1.3.52. SOTIO Biotech
      • 3.1.3.53. EXUMA Biotech
      • 3.1.3.54. ImmPACT Bio
      • 3.1.3.55. Kyverna Therapeutics
      • 3.1.3.56. Ucello Therapeutics
      • 3.1.3.57. Mustang Bio
      • 3.1.3.58. Wugen
      • 3.1.3.59. Inceptor Bio
      • 3.1.3.60. Tessa Therapeutics
      • 3.1.3.61. Immuneel Therapeutics
      • 3.1.3.62. OriCell Therapeutics
      • 3.1.3.63. Carina Biotech
      • 3.1.3.64. Juventas Cell Therapy
      • 3.1.3.65. Arsenal Biosciences
      • 3.1.3.66. Synthekine
      • 3.1.3.67. IASO Biotherapeutics
      • 3.1.3.68. MPC Therapeutics
      • 3.1.3.69. OriCell Therapeutics
      • 3.1.3.70. Verismo Therapeutics
      • 3.1.3.71. Cargo Therapeutics
      • 3.1.3.72. OneChain Immunotherapeutics
      • 3.1.3.73. Caribou Biosciences
      • 3.1.3.74. Verismo Therapeutics
      • 3.1.3.75. Kyverna Therapeutics
      • 3.1.3.76. Gracell Biotechnologies
      • 3.1.3.77. Cellares
      • 3.1.3.78. Celyad Oncology

4. IPO FUNDING RAISED BY CAR-T CELL THERAPY COMPANIES

  • 4.1. IPO Funds Raised by CAR-T Compamies - Deal Terms & Values
    • 4.1.1. Juno Therapeutics
    • 4.1.2. Cellular Biomedicine Group
    • 4.1.3. Xenetic Biosciences
    • 4.1.4. Cellular Biomedicine Group
    • 4.1.5. Autolus Therapeutics
    • 4.1.6. Allogene Therapeutics
    • 4.1.7. Precision BioSciences
    • 4.1.8. Atara Biotherapeutics
    • 4.1.9. Xenetic Biosciences
    • 4.1.10. Cabaletta Bio
    • 4.1.11. Atara Biotherapeutics
    • 4.1.12. Legend Biotech
    • 4.1.13. Mustang Bio
    • 4.1.14. JW Therapeutics
    • 4.1.15. Atara Biotherapeutics
    • 4.1.16. Gracell Biotechnologies
    • 4.1.17. Vor Biopharma
    • 4.1.18. Adicet Bio
    • 4.1.19. CARsgen Therapeutics
    • 4.1.20. Xenetic Biosciences
    • 4.1.21. Caribou Biosciences
    • 4.1.22. Celyad Oncology
    • 4.1.23. Adicet Bio
    • 4.1.24. Legend Biotech
    • 4.1.25. Kyverna Therapeutics
    • 4.1.26. Arcellx
    • 4.1.27. TC Biopharm
    • 4.1.28. Celularity
    • 4.1.29. TC BioPharm
    • 4.1.30. Precision Biosciences
    • 4.1.31. Legend Biotech
    • 4.1.32. TC Biopharm
    • 4.1.33. Vor Biopharma
    • 4.1.34. Precigen
    • 4.1.35. TC Biopharm
    • 4.1.36. Celularity
    • 4.1.37. Legend Biotech
    • 4.1.38. Coeptis Therapeutics
    • 4.1.39. Caribou Biosciences

5. CAR-T LICENSING DEALS EXECUTED GLOBALLY

  • 5.1. Total Value of CAR-T Licensing Deals Worldwide
    • 5.1.1. Descriptions of CAR-T Licensing Deals - Deal Terms & Values
      • 5.1.1.1. Cellectis & Ohio State University
      • 5.1.1.2. bluebird bio & Five Prime Therapeutics
      • 5.1.1.3. Poseida Therapeutics & Janssen Biotech
      • 5.1.1.4. bluebird bio & ViroMed
      • 5.1.1.5. Bellicum Pharmaceuticals & Astellas Pharma
      • 5.1.1.6. CRISPR Therapeutics & MaxCyte
      • 5.1.1.7. bluebird bio & Novartis
      • 5.1.1.8. Novartis & Celyad
      • 5.1.1.9. TC Biopharm & University College London (UCL)
      • 5.1.1.10. Mustang Bio & Fred Hutchinson Cancer Research Center
      • 5.1.1.11. Mustang Bio & Harvard University
      • 5.1.1.12. bluebird bio & TC Biopharm
      • 5.1.1.13. Janssen Biotech & Legend Biotech
      • 5.1.1.14. Autolus & UCL Business
      • 5.1.1.15. Otsuka Pharmaceutical & Osaka University
      • 5.1.1.16. Cellular Biomedicine & Novartis
      • 5.1.1.17. CRISPR Therapeutics & MaxCyte
      • 5.1.1.18. Wugen & Washington University
      • 5.1.1.19. Atara Biotherapeutics & Memorial Sloan Kettering Cancer Center
      • 5.1.1.20. bluebird bio & Inhibrx
      • 5.1.1.21. Autolus Therapeutics & Noile-Immune Biotech
      • 5.1.1.22. Vor Biopharma & MaxCyte
      • 5.1.1.23. Juno Therapeutics & Oxford Biomedica
      • 5.1.1.24. Allogene Therapeutics & MaxCyte
      • 5.1.1.25. Kite & Teneobio
      • 5.1.1.26. Legend Biotech & Noile-Immune Biotech
      • 5.1.1.27. Caribou Biosciences & MaxCyte
      • 5.1.1.28. Prescient Therapeutics & University of Pennsylvania
      • 5.1.1.29. Minerva Biotechnologies & Memorial Sloan Kettering Cancer Center
      • 5.1.1.30. Luminary Therapeutics & Case Western Reserve University
      • 5.1.1.31. Beam Therapeutics & Oxford Biomedica
      • 5.1.1.32. SOTIO Biotech & Unum Therapeutics
      • 5.1.1.33. Vor Biopharma & Metagenomi
      • 5.1.1.34. Chimeric Therapeutics & City of Hope
      • 5.1.1.35. Vor Biopharma & Arbor Biotechnologies
      • 5.1.1.36. Immuneel Therapeutics & Hospital Clinic de Barcelona (HCB)
      • 5.1.1.37. Vor Biopharma & National Cancer Institute (NCI)
      • 5.1.1.38. Caribou Biosciences & Memorial Sloan Kettering Cancer Center
      • 5.1.1.39. Carina Biotech & Bionomics
      • 5.1.1.40. Atara Biotherapeutics & Bayer
      • 5.1.1.41. Cellectis & SIRION Biotech
      • 5.1.1.42. Eli Lilly & Precision BioSciences
      • 5.1.1.43. AbbVie & Caribou Biosciences
      • 5.1.1.44. Luminary Therapeutics & Bio-Techne Corporation
      • 5.1.1.45. Wugen & HCW Biologics
      • 5.1.1.46. Alpha Biopharma & Wugen
      • 5.1.1.47. Servier & Precision Biosciences
      • 5.1.1.48. Dr. Reddy's Laboratories & Pregene Biopharma
      • 5.1.1.49. Celularity & MaxCyte
      • 5.1.1.50. BioNTech & Takara Bio
      • 5.1.1.51. Bellicum Pharmaceuticals & UNC Lineberger
      • 5.1.1.52. Mustang Bio & Mayo Clinic
      • 5.1.1.53. Precision Biosciences & Tiziana Sciences
      • 5.1.1.54. Arcellx & Oxford Biomedica
      • 5.1.1.55. Carina Biotech & BayPAT
      • 5.1.1.56. Inceptor Bio & University of California
      • 5.1.1.57. Rebirthel & Otsuka Pharmaceutical
      • 5.1.1.58. Kyverna Therapeutics & National Institutes of Health (NIH)
      • 5.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 5.1.1.60. Antion Biosciences & Allogene Therapeutics
      • 5.1.1.61. Sana Biotechnology & IASO Biotherapeutics
      • 5.1.1.62. CellPoint & Pregene
      • 5.1.1.63. Xenetic Biosciences
      • 5.1.1.64. GO Therapeutics
      • 5.1.1.65. LG Chem & MaxCyte
      • 5.1.1.66. Roche & Poseida Therapeutics
      • 5.1.1.67. Chugai Pharmaceutical & Noile-Immune Biotech
      • 5.1.1.68. Beam Therapeutics & Orbital Therapeutics
      • 5.1.1.69. Undisclosed Company & Oxford Biomedica
      • 5.1.1.70. Coeptis Therapeutics & University of Pittsburgh
      • 5.1.1.71. Cabaletta Bio & IASO Biotherapeutics
      • 5.1.1.72. Inceptor Bio & Avectas
      • 5.1.1.73. Kite Pharma & Refuge Biotechnologies
      • 5.1.1.74. Kite Pharma & Arcellx
      • 5.1.1.75. Cabaletta Bio & Autolus Therapeutics
      • 5.1.1.76. Precigen & Alaunos
      • 5.1.1.77. Leucid Bio & ImaginAb
      • 5.1.1.78. Affini-T Therapeutics & MSK
      • 5.1.1.79. Shunxi Holding & Cartherics
      • 5.1.1.80. Janssen Biotech & Cellular Biomedicine
      • 5.1.1.81. Astellas Pharma & Poseida Therapeutics
      • 5.1.1.82. Imugene & Precision Biosciences
      • 5.1.1.83. Cabaleta Bio & Oxford Biomedica
      • 5.1.1.84. Kyverna Therapeutics & Oxford Biomedica
      • 5.1.1.85. Coeptis Therapeutics & Univerdity of Pittsburgh

6. CAR-T COLLABORATION DEALS

  • 6.1. CAR-T Collaboration Deals between 2013 and 2023
    • 6.1.1. Descriptions of CAR-T Collaboration Deals Signed 2013 to 2023
      • 6.1.1.1. bluebird Bio & Celgene Corporation
      • 6.1.1.2. Pfizer, Inc. & Cellectis
      • 6.1.1.3. Amgen & Kite Pharma
      • 6.1.1.4. Five Prime Therapeutics & bluebird bio
      • 6.1.1.5. Celgene & Juno Therapeutics
      • 6.1.1.6. Cellectis & Servier
      • 6.1.1.7. Kite Pharma & Cell Design Labs
      • 6.1.1.8. Kite Pharma & Fosun Pharma
      • 6.1.1.9. Cellular Biomedicine Group & GE Healthcare Life Sciences, China
      • 6.1.1.10. Novartis & bluebird bio & Celyad
      • 6.1.1.11. Mustang Bio & Harvard University & Beth Israel Deaconess Medical
      • 6.1.1.12. Jenssen Biotech & Legend Biotech
      • 6.1.1.13. PersonGen & Anke Cellular Therapeutics & Miltenyi Biotec
      • 6.1.1.14. Kite Pharma & Sangamo Therapeutics
      • 6.1.1.15. bluebird bio & Celgene Corporation
      • 6.1.1.16. AbbVie & Calibr
      • 6.1.1.17. Novartis & Fraunhofer IZI
      • 6.1.1.18. Cellular Biomedicine & Novartis
      • 6.1.1.19. Regeneron Pharmaceuticals & bluebird bio
      • 6.1.1.20. Cartherics & ToolGen
      • 6.1.1.21. TC Biopharm & Dublin's Trinity College
      • 6.1.1.22. MaxCyte & Kite Pharma
      • 6.1.1.23. Phanes Therapeutics & Phanes Biopharmaceuticals & Fosun Kite
      • 6.1.1.24. Cellectis SA & Servier Monde
      • 6.1.1.25. MaxCyte & Allogene Therapeutics
      • 6.1.1.26. Fate Therapeutics & Janssen Biotech
      • 6.1.1.27. bluebird bio & Bristol Myers Squibb
      • 6.1.1.28. Xenetic Biosciences & PJSC Pharmsynthez
      • 6.1.1.29. Fate Therapeutics & Baylor College of Medicine
      • 6.1.1.30. Beam Therapeutics & Oxford Biomedica
      • 6.1.1.31. Carina Biotech & Glytherix
      • 6.1.1.32. Chimeric Therapeutics & City of Hope
      • 6.1.1.33. Biosceptre & Carina Biotech
      • 6.1.1.34. Allogene Therapeutics & University of Texas MD Anderson Center
      • 6.1.1.35. Oxford Biomedica & PhoreMost Limited
      • 6.1.1.36. Carina Biotech & Bionomics
      • 6.1.1.37. Bayer AG & Atara Biotherapeutics
      • 6.1.1.38. Oncternal Therapeutics & Karolinska Instituet
      • 6.1.1.39. EXUMA Biotech & Moffitt Cancer Center
      • 6.1.1.40. AbbVie & Caribou Biosciences
      • 6.1.1.41. Cytovia Therapeutics & Cellectis SAS
      • 6.1.1.42. JW Therapeutics & Thermo Fisher Scientific
      • 6.1.1.43. AbbVie & Caribou Biosciences
      • 6.1.1.44. Wugen & Alpha Biopharma
      • 6.1.1.45. Dr. Reddy's Laboratories & Shenzhen Pregene Biopharma
      • 6.1.1.46. Vor Biopharma & Abound Bio
      • 6.1.1.47. Kite Pharma & Fosun Pharmaceutical
      • 6.1.1.48. Takara Bio & BioNTech
      • 6.1.1.49. Vor Biopharma & Janssen Biotech
      • 6.1.1.50. Imugene & Celularity
      • 6.1.1.51. Gracell Biotechnologies & FutureGen Biopharm
      • 6.1.1.52. AdAlta & Carina Biotech
      • 6.1.1.53. Celularity & Oncternal Therapeutics
      • 6.1.1.54. Autolus Therapeutics & Blackstone Life Sciences
      • 6.1.1.55. 4basebio & Leucid Bio
      • 6.1.1.56. Leucid Bio & Lonza
      • 6.1.1.57. Oxford Biomedica & Arcellx
      • 6.1.1.58. Carina Biotech & Bayerische Patentallianz (BayPAT)
      • 6.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 6.1.1.60. Arsenal Biosciences & Bristol Myers Squibb
      • 6.1.1.61. Allogene Therapeutics & Antion Biosciences
      • 6.1.1.62. Transgene & PersonGen BioTherapeutics
      • 6.1.1.63. Immatics & Bristol Myers Squibb
      • 6.1.1.64. Legend Biotech & Janssen Biotech
      • 6.1.1.65. Umoja Biopharma & Lupagen
      • 6.1.1.66. Immatics & Celgene
      • 6.1.1.67. Immatics & Bristol Myers Squibb
      • 6.1.1.68. Umoja Biopharma & TreeFrog Therapeutics
      • 6.1.1.69. Invectys & University of Texas Cancer Center
      • 6.1.1.70. Poseida Therapeutics & Roche
      • 6.1.1.71. Chugai Pharmaceutical & Noile-Immune Biotech
      • 6.1.1.72. Kite Pharma & Arcellx
      • 6.1.1.73. Arsenal Biosciences & Genentech
      • 6.1.1.74. Autolus Therapeutics & Bristol Myers Squibb
      • 6.1.1.75. Inceptor Bio & Avectos
      • 6.1.1.76. JW Therapeutics & 2seventy bio
      • 6.1.1.77. Peter MacCallum Cancer Centre and Cartherics
      • 6.1.1.78. Umoja Biopharma & IASO Biotherapeutics
      • 6.1.1.79. Kite Pharma & Arcellx
      • 6.1.1.80. Ori Biotech & Inceptor Bio
      • 6.1.1.81. Simnova & Orna Therapeutics
      • 6.1.1.82. CARsgen Therapeutics & Huadong Medicine
      • 6.1.1.83. TC Biopharm & University of Texas MD Anderson Cancer Center
      • 6.1.1.84. Kite Pharma & Arcellx
      • 6.1.1.85. Peter MacCallum Cancer Centre & Cartherics
      • 6.1.1.86. Cartherics & Shunxi Holding Group
      • 6.1.1.87. Autolus Therapeutics & Cardinal Health
      • 6.1.1.88. Cartherics & Shunxi
      • 6.1.1.89. Janssen Biotech & Cellular Biomedicine
      • 6.1.1.90. CytoMed Therapeutics & University of Texas MD Anderson Cancer
      • 6.1.1.91. Noile-Immune Biotech & Sysmex
      • 6.1.1.92. GenScript Biotech & T-MAXIMUM Biotech
      • 6.1.1.93. CytoMed Therapeutics & Hangzhou CNK Therapeutics
      • 6.1.1.94. CARsgen Therapeutics & Moderna
      • 6.1.1.95. Cellares & Bristol Myers Squibb
      • 6.1.1.96. Celularity & Regeneron Pharmaceuticals
      • 6.1.1.97. Verily & Kyverna Therapeutics
      • 6.1.1.98. Kyverna Therapeutics & Elevate Bio

7. CAR-T INDUSTRY M&A DEALS (MERGER AND ACQUISITION)

  • 7.1. Globally Executed M&A Deals within the CAR-T Cell Therapy Sector - Terms and Values
    • 7.1.1. Cellular Biomedicine & Chinese PLA General Hospital
    • 7.1.2. Gilead Sciences & Kite Pharma
    • 7.1.3. Gilead Sciences & Cell Design Labs
    • 7.1.4. Novartis & Endocyte
    • 7.1.5. Bristol Myers Squibb & Celgene
    • 7.1.6. Xenetic Biosciences & Scripps Research Institute
    • 7.1.7. Astellas Pharma & Xyphos Biosciences
    • 7.1.8. BioNTech & Neon Therapeutics
    • 7.1.9. resTORbio & Adicet Bio
    • 7.1.10. Century Therapeutics & Empirica Therapeutics
    • 7.1.11. Celularity & GX Acquisition
    • 7.1.12. Cellular Biomedicine & CBMG Merger Sub
    • 7.1.13. Amgen & Five Prime Therapeutics
    • 7.1.14. BioNTech & Kite
    • 7.1.15. ImmPACT Bio & Kalthera
    • 7.1.16. Kiromic Biopharma & InSilico Solutions
    • 7.1.17. Allogene Therapeutics & Antion Biosciences
    • 7.1.17. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.18. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.19. Galapagos & CellPoint/AboundBio
    • 7.1.20. Atossa Therapeutics & Dynamic Cell Therapies
    • 7.1.21. Kite & Tmunity Therapeutics
    • 7.1.22. Janssen & Cellular Biomedicine
    • 7.1.23. Mustang Bio & uBriGene Biosciences
    • 7.1.24. Precision Biosciences & Imugene
    • 7.1.25. Oxford Biomedica & Institut Merieux
    • 7.1.26. Clade Therapeutics & Gadeta
    • 7.1.27. Kyowa Kirin & Orchard Therapeutics

8. PROFILES OF CAR-T COMPANIES INVOLVED WITH FUNDING EVENTS

  • 8.1. AdAlta Ltd.
  • 8.2. Adicet Bio
    • 8.2.1. Gamma Delta T Cells
  • 8.3. AffyImmune Therapeutics, Inc.
    • 8.3.1. Affinity-Tuned CARs
    • 8.3.2. Real-Time CAR-T Cell Monitoring
  • 8.4. Allogene Therapeutics
    • 8.4.1. AlloCAR-T
  • 8.5. Alpha Biopharma
  • 8.6. Antion Biosciences
    • 8.6.1. miCAR-T Technology
  • 8.7. Arcellx, Inc.
    • 8.7.1. D-Domain Technology
    • 8.7.2. ddCAR
    • 8.7.3. ARC-SparX
  • 8.8. Arsenal Biosciences, Inc.
  • 8.9. Astellas Pharma, Inc.
    • 8.9.1. Partnering
  • 8.10. Atara Biotherapeutics
  • 8.11. Autolus Therapeutics PLC
  • 8.12. AvenCell Therapeutics, Inc.
    • 8.12.1. Universal Switchable CAR Platform
  • 8.13. Beam Therapeutics
  • 8.14. Bellicum Pharmaceuticals, Inc.
    • 8.14.1. GoCAR Technology
    • 8.14.2. CaspaCIDe Technology
  • 8.15. Biosceptre
    • 8.15.1. The Unique Target: nfP2X7
  • 8.16. BioNTech SE
    • 8.16.1. Neoantigen-based T Cell Therapy Platform
  • 8.17. bluebird bio
  • 8.18. Cargo Therapeutics
  • 8.19. Caribou Biosciences, Inc.
    • 8.19.1. Next-Generation CRISR Technology
    • 8.19.1. CAR-T Therapy Platform
  • 8.20. Carina Biotech
    • 8.20.1. LGR5 CAR-T Program
  • 8.21. CARsgen Therapeutics Holdings Limited
    • 8.21.1. CycloCAR
    • 8.21.2. THANK-uCAR
  • 8.22. Cartherics Pty Ltd
    • 8.22.1. Cartherics' CAR-T Cells
  • 8.23. Cellares
    • 8.23.1. Cell Shuttle
  • 8.24. Cellectis
  • 8.25. Cellular Biomedicine Group
  • 8.26. Celularity, Inc.
    • 8.26.1. Power of the Placenta
    • 8.26.2. NK Cell Platform
    • 8.26.3. T Cell Platform
    • 8.26.4. Exosome Platform
  • 8.27. Celyad Oncology
    • 8.27.1. shRNA Platform
    • 8.27.2. shARC Platform
  • 8.28. Chengdu Usano Biotechnology Co., ltd. (Ucello)
  • 8.29. Chimeric Therapeutics, Ltd.
    • 8.29.1. CLTX CAR-T
    • 8.29.2. CDH17 CAR-T
  • 8.30. Clade Therapeutics
    • 8.30.1. Platform Technologies
  • 8.31. Coeptis Therapeutics, Inc.
    • 8.31.1. SNAP-CAR
  • 8.32. CRISPR Therapeutics
  • 8.33. Currus Biologics
    • 8.33.1. BEAT Technology
  • 8.34. CytoMed Therapeutics Ltd.
    • 8.34.1. CAR-yDelta- T Cell
  • 8.35. Dynamic Cell Therapies, Inc.
    • 8.35.1. Platform Technology
  • 8.36. Elicera Therapeutics
  • 8.37. Galapagos NV
  • 8.38. Gracell Biotechnologies
    • 8.38.1. FasTCAR
    • 8.38.2. TruUCAR
    • 8.38.3. SMART CART
  • 8.39. EXUMA Biotech Corp.
    • 8.39.1. TMR CAR-T Technology
  • 8.40. IASO Biotherapeutics
    • 8.40.1. Technology Platforms
  • 8.41. Immuneel Therapeutics, Pvt., Ltd.
  • 8.42. ImmPACT Bio
    • 8.42.1. CD19/20 Bispecific CAR
    • 8.42.2. TGF-B
  • 8.43. Inceptor Bio
    • 8.43.1. CAR-M Therapies
  • 8.44. Interius BioTherapeutics
  • 8.45. Invectys, Inc.
    • 8.45.1. IVS-3001: Anti HLA-G CAR-T Cells
  • 8.46. Juventas Cell Therapy, Ltd.
  • 8.47. JW Therapeutics
    • 8.47.1. Carteyva (relma-cel)
  • 8.48. Galapagos NV
    • 8.48.1. Platform Technology
  • 8.49. Kite Pharma (Gilead)
  • 8.50. Kyverna Therapeutics
    • 8.50.1. "Smarter" CAR-T Cells
  • 8.51. Legend Biotech
    • 8.51.1. Carvykti
  • 8.52. Leucid Bio, Ltd.
    • 8.52.1. Lateral CAR Platform
  • 8.53. Luminary Therapeutics
    • 8.53.1. Gamma 2.0+ Platform
  • 8.54. Lupagen, Inc.
    • 8.54.1. Side CAR-T Delivery System
  • 8.55. MaxCyte, Inc.
  • 8.56. Minerva Biotechnologies
  • 8.57. Mustang Bio, Inc.
  • 8.58. Noile-Immune Biotech
    • 8.58.1. PRIME Technology
  • 8.59. Novartis AG
    • 8.59.1. Approval of Kymriah
  • 8.60. OneChain Immunotherapeutics
  • 8.61. Oncternal Therapeutics, Inc
  • 8.61. ROR1
  • 8.62. OriCell Therapeutics
    • 8.62.1. OriCAR
  • 8.63. Oxford Biomedica PLC
    • 8.63.1. Lentivector Platform
    • 8.63.2. Adeno-Associated Virus Platform
  • 8.64. Pepromene Bio, Inc.
    • 8.64.1. BAFFR CAR-T Cells
  • 8.65. PersonGen Bio Therapeutics (Suzhou) Co., Ltd
  • 8.66. Poseida Therapeutics, Inc.
    • 8.66.1. PiggyBac Platform
    • 8.66.2. CasCLOVER Platform
  • 8.67. Precigen, Inc.
    • 8.67.1. UltraCAR-T Platform
  • 8.68. Precision BioSciences
    • 8.68.1. ARCUS Gene-Editing Platform
  • 8.69. Prescient Therapeutics
    • 8.69.1. OmniCAR
    • 8.69.2. CellPryme-M
    • 8.69.3. CellPryme-A
  • 8.70. Simnova Biotherapeutics
    • 8.70.1. BiTE CAR-T Platform
  • 8.71. SOTIO Biotech B.V.
  • 8.72. TC BioPharm
    • 8.72.1. Gamma Delta T Cells
    • 8.72.2. T Cell Banks
    • 8.72.3. Co-Stim CAR-T
  • 8.73. Umoja Biopharma
    • 8.73.1. VivoVec In Vivo Gene Delivery
    • 8.73.2. RACR-Induced Cytotoxic Lymphocytes (iCIL)
    • 8.73.3. RACR/CAR In Vivo Cell Programming
    • 8.73.4. TumorTag
  • 8.74. Verismo Therapeutics, Inc.
    • 8.74.1. KIR-CAR Platform
  • 8.75. Vor Biopharma
  • 8.76. Wugen, Inc.
  • 8.77. Xenetic Biosciences, Inc.
    • 8.77.1. XBIO-020: DNase I Armored CAR-T
  • 8.78. Xyphos Biosciences, Inc.
    • 8.78.1. covertibleCAR Technology

INDEX OF FIGURES

  • FIGURE 2.1: Sales Revenues of U.S. FDA-Approved CAR-T Therapies, 2017 to 2023
  • FIGURE 3.1: Total Venture Capital (VC) Raised by CAR-T Companies Worldwide, 2014 to 2023
  • FIGURE 4.1: Total IPO Funds Raised by CAR-T Cell Therapy Companies Worldwide, 2014 to 2023

INDEX OF TABLES

  • TABLE 1.1: All Known CAR-T Fundraising Deals Worldwide, 2014 to Present (Trailing 10 Years)
  • TABLE 2.1: Number of Patients Treated with CAR-T Therapies, 2017 - 2023
  • TABLE 3.1: Venture Capital Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 4.1: IPO Funds Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 5.1: CAR-T Licensing Deals Worldwide, 2015 to Present
  • TABLE 6.1: CAR-T Collaboration Deals Signed Worldwide, 2013 to Present (Trailing 10 Years)
  • TABLE 7.1: CAR-T M&A Deals Signed Worldwide, 2015 to Present